Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1NCT00702572
Official study title

Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer

Study summary

The primary objective of the study is to establish the phase II recommended dose of Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and bevacizumab for patients with previously untreated advanced non-small cell lunc cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedVorinostat, Bevacizumab, Carboplatin, Paclitaxel and Vorinostat, Bevacizumab, Carboplatin, Paclitaxel

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 22, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Milton S. Hershey Medical Center

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Milton S. Hershey Medical Center
Interventions being studied
Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel; Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Advanced non-squamous NSCLC
  • No prior chemotherapy for advanced disease
  • ECOG performance status 0 or 1
  • Measurable disease
  • Life expectancy \> 3 months
  • Normal bone marrow, renal and hepatic function
  • Ability to take oral medications
  • Willingness to sign informed consent
Reasons someone may not be able to joinExclusion criteria
  • History of brain metastasis
  • Evidence of thromboembolic phenomenon and treatment with anticoagulants
  • Pregnancy
  • Uncontrolled inter-current illness
  • Prior therapy with Paclitaxel

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Penn State College of Medicine, Penn State Milton S. Hershey Medical CenterHershey, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 22, 2016. Always confirm current availability with the study team.

View original record ↗